Pretreatment plasma testosterone and estradiol levels in patients with locally advanced or metastasized prostatic cancer

Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients

“…It seems that free testosterone serum levels do not correlate with PSA [1,4,5]. Low testosterone serum levels have been shown to predict locally advanced and high grade disease [2,3,[6][7][8][9][10][11]; however, these findings have not been confirmed in other studies [5,12]. Investigators have shown that low testosterone pretreatment serum levels may predict biochemical recurrence, disease progression and disease-specific survival [13][14][15][16][17][18][19], while others did not confirm this evidence [20].…”

“…Low free testosterone levels may increase the detection rate of prostate biopsies [1,2,[21][22][23]. Many authors have failed to show the value of free testosterone serum levels in predicting extracapsular extension or high grade prostate cancer [5, 12,24], while some others demonstrated the opposite [25]. Recently, it has been shown that the ratio of testosterone to PSA, significantly decreased in eugonadal (PSA C 3 and \ 10.0 ng/mL) and hypogonadal men (PSA 4.0 ng/mL or less) with prostate cancer undergoing TRUSB, was highly predictive of the disease [26,27].…”

Pretreatment Serum Level of Testosterone as a Prognostic Factor in Japanese Men with Hormonally Treated Stage D2 Prostate Cancer.

“…A NUMBER of clinical, endocrinological and pathological prognostic factors for prostate cancer have been reported [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15][16]. Knowledge of these factors will likely contribute to determining the most appropriate therapy for individual patients.…”

Is Immunohistochemical Sex Hormone Binding Globulin Expression Important in the Differential Diagnosis of Adenocarcinomas?

“…As mentioned above, many studies have reported, with equivocal results, the search for associations between the plasma levels of SHBG and prognoses of male and female genital organ cancers (Barrett-Connor et al, 1990;Grasso et al, 1990;Gann et al, 1996;Guess et al, 1997;Dorgan et al, 1998;Mikkola et al, 1999;Lee et al, 2008). Likewise, research papers have also been published focusing on the search for additional information about extratumoral mechanisms and the causes of changes in the plasma SHBG levels.…”